Holen Sie sich die Stockscreener-App
7.52
0.40%
0.03
Handel nachbörslich:
7.52
Trevi Therapeutics Inc Aktie (TRVI) Neueste Nachrichten
Trendline Breach Raises Concern for Trevi Therapeutics Inc. InvestorsInsider Buying & Community Shared Stock Ideas - 선데이타임즈
Is This the Dip to Buy in Trevi Therapeutics Inc.Portfolio Risk Summary & Reliable Intraday Trade Alerts - classian.co.kr
Trevi Therapeutics: Optimism Amid Earnings Call Insights - MSN
Healthcare Analysts Offer Insights on Trevi Therapeutics, DENTSPLY SIRONA, and Arrowhead Pharmaceuticals. - AInvest
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q2 2025 Earnings Call Transcript - Insider Monkey
Why Trevi Therapeutics Inc. stock attracts strong analyst attentionForward PE Discount Stocks - classian.co.kr
Trevi Therapeutics (NASDAQ:TRVI) Price Target Lowered to $22.00 at Needham & Company LLC - MarketBeat
JonesTrading Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $25 - 富途牛牛
Trevi Therapeutics outlines $204M cash runway into 2029 as Phase III programs advance following positive CORAL data - MSN
Trevi Therapeutics' Promising Developments and Strategic Expansion Bolster Growth Potential. - AInvest
Trevi Therapeutics' Path to Sustainable Growth and Value Creation - AInvest
Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans - uk.finance.yahoo.com
Trevi Therapeutics (TRVI): A High-Potential Biotech Play in Chronic Cough with a Clear Path to Phase 3 and FDA Alignment - AInvest
Trevi Therapeutics Gears Up For Next Phase After Positive Results - Finimize
Unlocking Long-Term Value: Trevi Therapeutics' Strategic Capital Efficiency and Robust Clinical Data Drive Phase III Momentum - AInvest
Transcript : Trevi Therapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Promising Phase 2b Results and Strong Financial Position Drive Buy Rating for Trevi Therapeutics - TipRanks
Earnings call transcript: Trevi Therapeutics Q2 2025 shows slight EPS beat - Investing.com Australia
Trevi Therapeutics Inc (TRVI) Q2 2025 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Trevi Therapeutics Inc (TRVI) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial Strength - GuruFocus
Trevi Therapeutics Reports Positive Trial Results and Financial Stability - TipRanks
Trevi Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Trevi Therapeutics Q2 EPS beats estimates - MarketScreener
Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates - PR Newswire
Trevi Therapeutics TRVI Q2 2025 Earnings Preview Upside Potential with Positive Share Dynamics - AInvest
Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025 - 富途牛牛
Is Trevi Therapeutics Inc. stock overvalued or undervaluedMassive profits - Jammu Links News
Should I hold or sell Trevi Therapeutics Inc. stock in 2025Free Investment Timing Strategies - Jammu Links News
What is the risk reward ratio of investing in Trevi Therapeutics Inc. stockUnlock daily stock market insights for success - Jammu Links News
What makes Trevi Therapeutics Inc. stock price move sharplyFree Market Dynamics Reports - Jammu Links News
Published on: 2025-08-03 17:59:19 - Jammu Links News
When is Trevi Therapeutics Inc. stock expected to show significant growthFree Buy/Sell Signal Notifications - Jammu Links News
How strong is Trevi Therapeutics Inc. company’s balance sheetUnlock powerful trading alerts for success - Jammu Links News
What analysts say about Trevi Therapeutics Inc. stockUnlock rapid growth potential in your portfolio - Jammu Links News
Why is Trevi Therapeutics Inc. stock attracting strong analyst attentionExceptional market performance - Jammu Links News
What institutional investors are buying Trevi Therapeutics Inc. stockMarket Forecast Recommendation With Low Risk - Jammu Links News
Trevi Therapeutics to Report Second Quarter 2025 Financial Resul - GuruFocus
Trevi Therapeutics Q2 Earnings: Key Updates on Chronic Cough Drug Trials Coming August 7 - Stock Titan
Is it the right time to buy Trevi Therapeutics Inc. stockEntry Signal Growth Plan For Every Investor - Jammu Links News
Trend analysis for Trevi Therapeutics Inc. this weekLow Risk Buy Zone Opportunity Watch Ongoing - metal.it
Has Trevi Therapeutics Inc. formed a bullish divergenceFundamental + Technical Combined Watchlist - Newser
Predicting Trevi Therapeutics Inc. trend using moving averagesRisk Balanced Picks for Safer Trading - Newser
Bullish Candlestick Pattern Forms in Trevi Therapeutics Inc.Weekly Stock Opportunity Radar Scanner Activated - metal.it
Developing predictive dashboards with Trevi Therapeutics Inc. dataDaily Market Entry Strategy with Tools - Newser
Trevi Therapeutics Inc. Earnings Report Breakdown: What Investors Should KnowWeekly Hot Stocks Based on Volume Flow - Newser
Trevi Therapeutics Inc.’s Beta Climbs After Market VolatilityAI Screening for Swing Trade Picks Finds Momentum - metal.it
Why did Trevi Therapeutics' operating expenses surge in Q3 2024? - AInvest
Trevi Therapeutics to Participate in Upcoming August Conferences - PR Newswire
Trevi Therapeutics Leadership Showcases Chronic Cough Treatment Progress at Major August Biotech Conferences - Stock Titan
Trevi Therapeutics Inc. Shows Early Signs of Technical StrengthFast Exit and Entry Strategy Guide Offered - metal.it
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):